48 – Hepatitis C vaccines

[1]  R. Bartenschlager,et al.  On the history of hepatitis C virus cell culture systems. , 2014, Journal of medicinal chemistry.

[2]  C. Rice,et al.  Expanded Classification of Hepatitis C Virus Into 7 Genotypes and 67 Subtypes: Updated Criteria and Genotype Assignment Web Resource , 2013, Hepatology.

[3]  A. Moreau,et al.  Rapid and sustained autologous neutralizing response leading to early spontaneous recovery after HCV infection. , 2013, Virology.

[4]  K. Ishii,et al.  Neutralizing antibodies induced by cell culture-derived hepatitis C virus protect against infection in mice. , 2013, Gastroenterology.

[5]  Charles M. Rice,et al.  Completion of the entire hepatitis C virus life-cycle in genetically humanized mice , 2013, Nature.

[6]  R. De Francesco,et al.  New horizons in hepatitis C antiviral therapy with direct‐acting antivirals , 2013, Hepatology.

[7]  William J. Rice,et al.  Ultrastructural analysis of hepatitis C virus particles , 2013, Proceedings of the National Academy of Sciences.

[8]  P. Klenerman,et al.  Ever closer to a prophylactic vaccine for HCV , 2013, Expert opinion on biological therapy.

[9]  A. Flaxman,et al.  Global epidemiology of hepatitis C virus infection: New estimates of age‐specific antibody to HCV seroprevalence , 2013, Hepatology.

[10]  Christopher T. Jones,et al.  A Hepatitis C Virus (HCV) Vaccine Comprising Envelope Glycoproteins gpE1/gpE2 Derived from a Single Isolate Elicits Broad Cross-Genotype Neutralizing Antibodies in Humans , 2013, PloS one.

[11]  J. Goedert,et al.  Genome-Wide Association Study of Spontaneous Resolution of Hepatitis C Virus Infection: Data From Multiple Cohorts , 2013, Annals of Internal Medicine.

[12]  R. Purcell,et al.  Human Monoclonal Antibody HCV1 Effectively Prevents and Treats HCV Infection in Chimpanzees , 2012, PLoS pathogens.

[13]  M. Imamura,et al.  Genetics of IL28B and HCV—response to infection and treatment , 2012, Nature Reviews Gastroenterology &Hepatology.

[14]  M. Manns,et al.  Sustained viral load reduction in treatment-naive HCV genotype 1 infected patients after therapeutic peptide vaccination. , 2012, Vaccine.

[15]  Heiyoung Park,et al.  Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion. , 2012, The Journal of infectious diseases.

[16]  A. Folgori,et al.  Vaccine Vectors Derived from a Large Collection of Simian Adenoviruses Induce Potent Cellular Immunity Across Multiple Species , 2012, Science Translational Medicine.

[17]  A. Folgori,et al.  Novel Adenovirus-Based Vaccines Induce Broad and Sustained T Cell Responses to HCV in Man , 2012, Science Translational Medicine.

[18]  S. Emerson,et al.  Vaccine-induced cross-genotype reactive neutralizing antibodies against hepatitis C virus. , 2011, The Journal of infectious diseases.

[19]  F. Cosset,et al.  Clearance of Genotype 1b Hepatitis C Virus in Chimpanzees in the Presence of Vaccine-Induced E1-Neutralizing Antibodies , 2011, The Journal of infectious diseases.

[20]  C. Bain,et al.  A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C. , 2011, Gastroenterology.

[21]  F. Negro,et al.  Current understanding of insulin resistance in hepatitis C , 2011, Expert review of gastroenterology & hepatology.

[22]  Charles M. Rice,et al.  A genetically humanized mouse model for hepatitis C virus infection , 2011, Nature.

[23]  H. Wedemeyer,et al.  Progress in the development of preventive and therapeutic vaccines for hepatitis C virus. , 2011, Journal of hepatology.

[24]  P. Klenerman,et al.  Molecular footprints reveal the impact of the protective HLA-A*03 allele in hepatitis C virus infection , 2011, Gut.

[25]  Olivier Poch,et al.  EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy , 2011, Nature Medicine.

[26]  Z. Nawaz,et al.  An overview of HCV molecular biology, replication and immune responses , 2011, Virology Journal.

[27]  C. Rice,et al.  A humanized mouse model to study hepatitis C virus infection, immune response, and liver disease. , 2011, Gastroenterology.

[28]  R. Purcell,et al.  In vivo evaluation of the cross‐genotype neutralizing activity of polyclonal antibodies against hepatitis C virus , 2011, Hepatology.

[29]  Raymond T Chung,et al.  Spontaneous control of HCV is associated with expression of HLA-B 57 and preservation of targeted epitopes. , 2011, Gastroenterology.

[30]  M. Houghton.  Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses , 2011, Immunological reviews.

[31]  H. El‐Serag,et al.  Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[32]  P. Roingeard,et al.  Role of N-Linked Glycans in the Functions of Hepatitis C Virus Envelope Proteins Incorporated into Infectious Virions , 2010, Journal of Virology.

[33]  K. Meyer,et al.  Characterization of antibodies induced by vaccination with Hepatitis C virus envelope glycoproteins , 2010, The Journal of infectious diseases.

[34]  R. Ray,et al.  Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. , 2010, Vaccine.

[35]  J. Dubuisson,et al.  Characterization of the Envelope Glycoproteins Associated with Infectious Hepatitis C Virus , 2010, Journal of Virology.

[36]  F. Negro.  Abnormalities of lipid metabolism in hepatitis C virus infection , 2010, Gut.

[37]  S. Lemon.  Induction and Evasion of Innate Antiviral Responses by Hepatitis C Virus* , 2010, The Journal of Biological Chemistry.

[38]  Sven Bergmann,et al.  Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. , 2010, Gastroenterology.

[39]  C. Klade,et al.  Immunogenicity and safety of different injection routes and schedules of IC41, a Hepatitis C virus (HCV) peptide vaccine. , 2010, Vaccine.

[40]  M. Houghton.  The long and winding road leading to the identification of the hepatitis C virus. , 2009, Journal of hepatology.

[41]  David B. Goldstein,et al.  Genetic variation in IL28B and spontaneous clearance of hepatitis C virus , 2009, Nature.

[42]  Thomas Berg,et al.  IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy , 2009, Nature Genetics.

[43]  T. Ide,et al.  Phase I clinical study of a peptide vaccination for hepatitis C virus‐infected patients with different human leukocyte antigen‐class I‐A alleles , 2009, Cancer science.

[44]  A. Koike,et al.  Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C , 2009, Nature Genetics.

[45]  Jacques Fellay,et al.  Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance , 2009, Nature.

[46]  M. Manns,et al.  Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C. , 2009, Vaccine.

[47]  T. Baumert,et al.  GI-5005, a yeast vector vaccine expressing an NS3-core fusion protein for chronic HCV infection. , 2009, Current opinion in molecular therapeutics.

[48]  Leticia Martínez,et al.  Toxicology and biodistribution study of CIGB-230, a DNA vaccine against hepatitis C virus , 2009, Human & experimental toxicology.

[49]  Hongxiang Sun,et al.  ISCOMs and ISCOMATRIX. , 2009, Vaccine.

[50]  P. Mavromara,et al.  The HCV ARFP/F/core+1 protein: Production and functional analysis of an unconventional viral product , 2009, IUBMB life.

[51]  S. Ray,et al.  Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus. , 2009, Gastroenterology.

[52]  William M. Lee,et al.  627 GI-5005 IMMUNOTHERAPY PLUS PEG-IFN/RIBAVIRIN VERSUS PEG-IFN/RIBAVIRIN IN GENOTYPE 1 CHRONIC HCV SUBJECTS; PRELIMINARY PHASE 2 EVR ANALYSES , 2009 .

[53]  M. Fons,et al.  43 a First Clinical Trial of Therapeutic Vaccination Using Naked Dna Delivered by in Vivo Electroporation Shows Antiviral Effects in Patients With Chronic Hepatitis C , 2009 .

[54]  M. Houghton,et al.  Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX™ vaccine: A phase I study in healthy volunteers , 2009, Human vaccines.

[55]  J. Dubuisson,et al.  Immunogenicity of CIGB‐230, a therapeutic DNA vaccine preparation, in HCV‐chronically infected individuals in a Phase I clinical trial , 2009, Journal of viral hepatitis.

[56]  J. Bukh,et al.  Development and characterization of hepatitis C virus genotype 1‐7 cell culture systems: Role of CD81 and scavenger receptor class B type I and effect of antiviral drugs , 2009, Hepatology.

[57]  Charles M. Rice,et al.  Human occludin is a hepatitis C virus entry factor required for infection of mouse cells , 2009, Nature.

[58]  C. Rice,et al.  CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells , 2009, The Journal of general virology.

[59]  A. Alberti.  What are the comorbidities influencing the management of patients and the response to therapy in chronic hepatitis C? , 2009, Liver international : official journal of the International Association for the Study of the Liver.

[60]  A. Folgori,et al.  Evidence for Protection against Chronic Hepatitis C Virus Infection in Chimpanzees by Immunization with Replicating Recombinant Vaccinia Virus , 2008, Journal of Virology.

[61]  J. McKeating,et al.  Hepatitis C virus entry and neutralization. , 2008, Clinics in liver disease.

[62]  S. Emerson,et al.  Apolipoprotein C1 Association with Hepatitis C Virus , 2008, Journal of Virology.

[63]  M. Carrington,et al.  Hepatitis C virus (HCV)-specific immune responses of long-term injection drug users frequently exposed to HCV. , 2008, The Journal of infectious diseases.

[64]  R. Purcell,et al.  Previously Infected Chimpanzees Are Not Consistently Protected against Reinfection or Persistent Infection after Reexposure to the Identical Hepatitis C Virus Strain , 2008, Journal of Virology.

[65]  A. Nicosia,et al.  Hepatitis C vaccine: supply and demand. , 2008, The Lancet. Infectious diseases.

[66]  M. Houghton,et al.  Induction of Broad CD4+ and CD8+ T-Cell Responses and Cross- Neutralizing Antibodies against Hepatitis C Virus by Vaccination with Th1-Adjuvanted Polypeptides Followed by Defective Alphaviral Particles Expressing Envelope Glycoproteins gpE1 and gpE2 and Nonstructural Proteins 3, 4, and 5 , 2008, Journal of Virology.

[67]  M. Manns,et al.  Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. , 2008, Gastroenterology.

[68]  M. Bernstein,et al.  Recombinant Saccharomyces cerevisiae (yeast-CEA) as a potent activator of murine dendritic cells. , 2008, Vaccine.

[69]  J. Bukh,et al.  Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization , 2008, Proceedings of the National Academy of Sciences.

[70]  J. McKeating,et al.  Hepatitis C virus cell‐cell transmission in hepatoma cells in the presence of neutralizing antibodies , 2007, Hepatology.

[71]  L. Chatel,et al.  An accelerated vaccine schedule with a poly-antigenic hepatitis C virus MVA-based candidate vaccine induces potent, long lasting and in vivo cross-reactive T cell responses. , 2007, Vaccine.

[72]  W. Ho,et al.  Deletion of N-glycosylation sites of hepatitis C virus envelope protein E1 enhances specific cellular and humoral immune responses. , 2007, Vaccine.

[73]  Y. Liaw.  Viral load in hepatitis B e antigen–negative carriers with normal aminotransferase level , 2007, Hepatology.

[74]  F. Penin,et al.  The Neutralizing Activity of Anti-Hepatitis C Virus Antibodies Is Modulated by Specific Glycans on the E2 Envelope Protein , 2007, Journal of Virology.

[75]  Zongyi Hu,et al.  Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees , 2007, Proceedings of the National Academy of Sciences.

[76]  M. Alter,et al.  Epidemiology of hepatitis C virus infection. , 2007, World journal of gastroenterology.

[77]  Charles M. Rice,et al.  Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry , 2007, Nature.

[78]  P. Schürmann,et al.  Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C , 2007, Proceedings of the National Academy of Sciences.

[79]  B. Bartosch,et al.  Vaccine‐induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD‐1 and chronicity , 2007, Hepatology.

[80]  G. Lauer,et al.  Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins. , 2007, Vaccine.

[81]  R. Thimme,et al.  Impact of the genetic restriction of virus-specific T-cell responses in hepatitis C virus infection , 2007, Genes and Immunity.

[82]  A. Folgori,et al.  Modulation of the Immune Response Induced by Gene Electrotransfer of a Hepatitis C Virus DNA Vaccine in Nonhuman Primates , 2006, The Journal of Immunology.

[83]  C. Voisset,et al.  High-density lipoproteins reduce the neutralizing effect of hepatitis C virus (HCV)-infected patient antibodies by promoting HCV entry. , 2006, The Journal of general virology.

[84]  Ralf Bartenschlager,et al.  High Density Lipoprotein Inhibits Hepatitis C Virus-neutralizing Antibodies by Stimulating Cell Entry via Activation of the Scavenger Receptor BI* , 2006, Journal of Biological Chemistry.

[85]  J. Blackard,et al.  Extrahepatic replication of HCV: Insights into clinical manifestations and biological consequences , 2006, Hepatology.

[86]  R. Chung,et al.  Management of hepatitis C virus coinfection in HIV-infected persons. , 2006, The AIDS reader.

[87]  C. Klade,et al.  Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects. , 2006, Vaccine.

[88]  A. Folgori,et al.  Efficient immunization of rhesus macaques with an HCV candidate vaccine by heterologous priming–boosting with novel adenoviral vectors based on different serotypes , 2006, Gene Therapy.

[89]  S. Poe,et al.  Adverse consequences of tattoos and body piercings. , 2006, Pediatric annals.

[90]  M. Manns,et al.  Early monotherapy with pegylated interferon alpha‐2b for acute hepatitis C infection: The HEP‐NET acute‐HCV‐II study , 2006, Hepatology.

[91]  A. Folgori,et al.  A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees , 2006, Nature Medicine.

[92]  F. Chisari,et al.  Immunobiology and pathogenesis of viral hepatitis. , 2006, Annual review of pathology.

[93]  A. Prince,et al.  Protection against chronic hepatitis C virus infection after rechallenge with homologous, but not heterologous, genotypes in a chimpanzee model. , 2005, The Journal of infectious diseases.

[94]  F. Chisari,et al.  Platelets mediate cytotoxic T lymphocyte–induced liver damage , 2005, Nature Medicine.

[95]  Christophe Combet,et al.  Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes , 2005, Hepatology.

[96]  M. Gale,et al.  Evasion of intracellular host defence by hepatitis C virus , 2005, Nature.

[97]  C. Walker,et al.  Adaptive immune responses in acute and chronic hepatitis C virus infection , 2005, Nature.

[98]  M. Houghton,et al.  Prospects for a vaccine against the hepatitis C virus , 2005, Nature.

[99]  Charles M. Rice,et al.  Unravelling hepatitis C virus replication from genome to function , 2005, Nature.

[100]  Toshiaki Maruyama,et al.  Complete Replication of Hepatitis C Virus in Cell Culture , 2005, Science.

[101]  F. Penin,et al.  An Interplay between Hypervariable Region 1 of the Hepatitis C Virus E2 Glycoprotein, the Scavenger Receptor BI, and High-Density Lipoprotein Promotes both Enhancement of Infection and Protection against Neutralizing Antibodies , 2005, Journal of Virology.

[102]  D. Burton,et al.  Robust hepatitis C virus infection in vitro. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[103]  C. Walker,et al.  Mutational escape from CD8+ T cell immunity , 2005, The Journal of experimental medicine.

[104]  J. Pawlotsky,et al.  Human Serum Facilitates Hepatitis C Virus Infection, and Neutralizing Responses Inversely Correlate with Viral Replication Kinetics at the Acute Phase of Hepatitis C Virus Infection , 2005, Journal of Virology.

[105]  P. Klenerman,et al.  Preferential loss of IL‐2–secreting CD4+ T helper cells in chronic HCV infection , 2005, Hepatology.

[106]  B. Chain,et al.  Is hepatitis C virus infection of dendritic cells a mechanism facilitating viral persistence? , 2005, The Lancet. Infectious diseases.

[107]  R. Hershow,et al.  Hepatitis C virus coinfection and HIV load, CD4+ cell percentage, and clinical progression to AIDS or death among HIV-infected women: Women and Infants Transmission Study. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[108]  C. Walker,et al.  The origin of quasispecies: cause or consequence of chronic hepatitis C viral infection? , 2005, Journal of hepatology.

[109]  D. Stump,et al.  The hepatitis C virus alternate reading frame (ARF) and its family of novel products: the alternate reading frame protein/F-protein, the double-frameshift protein, and others. , 2005, Seminars in liver disease.

[110]  P. André,et al.  Hepatitis C virus particles and lipoprotein metabolism. , 2005, Seminars in liver disease.

[111]  M. Pearse,et al.  ISCOMATRIX adjuvant for antigen delivery. , 2005, Advanced drug delivery reviews.

[112]  D. Sène,et al.  Hepatitis C Virus-Associated Extrahepatic Manifestations: A Review , 2004, Metabolic Brain Disease.

[113]  Joseph D. Puglisi,et al.  The Pathway of HCV IRES-Mediated Translation Initiation , 2004, Cell.

[114]  A. Folgori,et al.  Multispecific T cell response and negative HCV RNA tests during acute HCV infection are early prognostic factors of spontaneous clearance , 2004, Gut.

[115]  Y. Nagao,et al.  Hepatitis C virus and lichen planus , 2004, Journal of gastroenterology and hepatology.

[116]  P. André,et al.  Expression of hepatitis C virus proteins in epithelial intestinal cells in vivo. , 2004, The Journal of general virology.

[117]  Todd M. Allen,et al.  High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. , 2004, Gastroenterology.

[118]  B. Anand,et al.  Assessment of correlation between serum titers of hepatitis C virus and severity of liver disease. , 2004, World journal of gastroenterology.

[119]  G. Leroux-Roels,et al.  A candidate vaccine based on the hepatitis C E1 protein: tolerability and immunogenicity in healthy volunteers. , 2004, Vaccine.

[120]  C. la Vecchia,et al.  B‐cell non‐Hodgkin's lymphoma and hepatitis C virus infection: A systematic review , 2004, International journal of cancer.

[121]  Salim I. Khakoo,et al.  HLA and NK Cell Inhibitory Receptor Genes in Resolving Hepatitis C Virus Infection , 2004, Science.

[122]  C. Rice,et al.  Characterization of Infectious Retroviral Pseudotype Particles Bearing Hepatitis C Virus Glycoproteins , 2004, Journal of Virology.

[123]  Zongyi Hu,et al.  Immunization with Hepatitis C Virus-Like Particles Induces Humoral and Cellular Immune Responses in Nonhuman Primates , 2004, Journal of Virology.

[124]  H. Thomas,et al.  Identification of Unique Hepatitis C Virus Quasispecies in the Central Nervous System and Comparative Analysis of Internal Translational Efficiency of Brain, Liver, and Serum Variants , 2004, Journal of Virology.

[125]  M. Mizokami,et al.  Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. , 2003, Gastroenterology.

[126]  H. Van Vlierberghe,et al.  A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C , 2003, Hepatology.

[127]  Charles M. Rice,et al.  HCV Persistence and Immune Evasion in the Absence of Memory T Cell Help , 2003, Science.

[128]  J. Hoofnagle,et al.  Hepatitis C and renal disease: an update. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[129]  F. Penin,et al.  Membrane association of hepatitis C virus nonstructural proteins and identification of the membrane alteration that harbors the viral replication complex. , 2003, Antiviral research.

[130]  J. Ghrayeb,et al.  Memory CD8+ T Cells Are Required for Protection from Persistent Hepatitis C Virus Infection , 2003, The Journal of experimental medicine.

[131]  R. K. Evans,et al.  Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene , 2003, Journal of Virology.

[132]  C. Cheng‐Mayer,et al.  Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[133]  B. Bartosch,et al.  Infectious Hepatitis C Virus Pseudo-particles Containing Functional E1–E2 Envelope Protein Complexes , 2003, The Journal of experimental medicine.

[134]  M. Alter,et al.  Prevention of spread of hepatitis C , 2002, Hepatology.

[135]  J. Hoofnagle.  Course and outcome of hepatitis C , 2002, Hepatology.

[136]  L. Seeff,et al.  Natural history of chronic hepatitis C , 2002, Hepatology.

[137]  R. Cortese,et al.  The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus , 2002, The EMBO journal.

[138]  J. Hoofnagle,et al.  Impaired Effector Function of Hepatitis C Virus-Specific CD8+ T Cells in Chronic Hepatitis C Virus Infection1 , 2002, The Journal of Immunology.

[139]  P. André,et al.  Characterization of Low- and Very-Low-Density Hepatitis C Virus RNA-Containing Particles , 2002, Journal of Virology.

[140]  C. Rice,et al.  Previously Infected and Recovered Chimpanzees Exhibit Rapid Responses That Control Hepatitis C Virus Replication upon Rechallenge , 2002, Journal of Virology.

[141]  D. Vlahov,et al.  Protection against persistence of hepatitis C , 2002, The Lancet.

[142]  R. Bartenschlager,et al.  Interferon‐γ inhibits replication of subgenomic and genomic hepatitis C virus RNAs , 2002 .

[143]  M. Chen,et al.  Hepatitis C virus non-structural protein 3-specific cellular immune responses following single or combined immunization with DNA or recombinant Semliki Forest virus particles. , 2002, The Journal of general virology.

[144]  A. Musacchio,et al.  In vitro self-assembled HCV core virus-like particles induce a strong antibody immune response in sheep. , 2002, Biochemical and biophysical research communications.

[145]  C. Tseng,et al.  Binding of the Hepatitis C Virus Envelope Protein E2 to CD81 Inhibits Natural Killer Cell Functions , 2002, The Journal of experimental medicine.

[146]  S. Nuti,et al.  Inhibition of Natural Killer Cells through Engagement of CD81 by the Major Hepatitis C Virus Envelope Protein , 2002, The Journal of experimental medicine.

[147]  J. Dubuisson,et al.  Live and killed rhabdovirus-based vectors as potential hepatitis C vaccines. , 2002, Virology.

[148]  A. Tramontano,et al.  Mimotopes of the hyper variable region 1 of the hepatitis C virus induce cross-reactive antibodies directed against discontinuous epitopes. , 2001, Molecular immunology.

[149]  A. Hughes,et al.  The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. , 2001, Immunity.

[150]  F. Chisari,et al.  Determinants of Viral Clearance and Persistence during Acute Hepatitis C Virus Infection , 2001, The Journal of experimental medicine.

[151]  M. Houghton,et al.  Intrahepatic Genetic Inoculation of Hepatitis C Virus RNA Confers Cross-Protective Immunity , 2001, Journal of Virology.

[152]  T. Liang,et al.  Hepatitis C virus–like particles induce virus‐specific humoral and cellular immune responses in mice , 2001, Hepatology.

[153]  C. Valenzuela,et al.  A truncated HCV core protein elicits a potent immune response with a strong participation of cellular immunity components in mice. , 2001, Vaccine.

[154]  M. Houghton,et al.  Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection , 2001, Hepatology.

[155]  Y. Matsuura,et al.  Identification of immunodominant hepatitis C virus (HCV)‐specific cytotoxic T‐cell epitopes by stimulation with endogenously synthesized HCV antigens , 2001, Hepatology.

[156]  D. Stump,et al.  Evidence for a new hepatitis C virus antigen encoded in an overlapping reading frame. , 2001, RNA.

[157]  Chong-Kyo Lee,et al.  Immunogenicity of the E1E2 proteins of hepatitis C virus expressed by recombinant adenoviruses. , 2001, Vaccine.

[158]  T. Shikata,et al.  Prevention of hepatitis C virus infection in a chimpanzee by vaccination and epitope mapping of antiserum directed against hypervariable region 1. , 2001, Hepatology research : the official journal of the Japan Society of Hepatology.

[159]  S. Watowich,et al.  Self-Assembly of Nucleocapsid-Like Particles from Recombinant Hepatitis C Virus Core Protein , 2001, Journal of Virology.

[160]  M. Houghton,et al.  Characterization of Hepatitis C Virus Core-Specific Immune Responses Primed in Rhesus Macaques by a Nonclassical ISCOM Vaccine , 2001, The Journal of Immunology.

[161]  F. Zoulim,et al.  Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. , 2001, Gastroenterology.

[162]  S. Emerson,et al.  Vaccination of Chimpanzees With Plasmid DNA Encoding the Hepatitis C Virus (HCV) Envelope E2 Protein Modified the Infection After Challenge With Homologous Monoclonal HCV , 2000, Hepatology.

[163]  P. Klenerman,et al.  CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained , 2000, European journal of immunology.

[164]  M. Houghton,et al.  Evaluation of Hepatitis C Virus Glycoprotein E2 for Vaccine Design: an Endoplasmic Reticulum-Retained Recombinant Protein Is Superior to Secreted Recombinant Protein and DNA-Based Vaccine Candidates , 2000, Journal of Virology.

[165]  M. Perkus,et al.  DNA prime-canarypox boost with polycistronic hepatitis C virus (HCV) genes generates potent immune responses to HCV structural and nonstructural proteins. , 2000, The Journal of infectious diseases.

[166]  B. Walker,et al.  Analysis of Successful Immune Responses in Persons Infected with Hepatitis C Virus , 2000, The Journal of experimental medicine.

[167]  H J Alter,et al.  The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. , 2000, Science.

[168]  Y. Sung,et al.  Enhancement of Immunoglobulin G2a and Cytotoxic T-Lymphocyte Responses by a Booster Immunization with Recombinant Hepatitis C Virus E2 Protein in E2 DNA-Primed Mice , 2000, Journal of Virology.

[169]  A. Alberti,et al.  Natural history of hepatitis C. , 1999, Journal of hepatology.

[170]  L. Magder,et al.  The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt , 2000, The Lancet.

[171]  V. Agnello,et al.  Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[172]  Alessandro Sette,et al.  Conserved hepatitis C virus sequences are highly immunogenic for CD4+ T cells: Implications for vaccine development , 1999, Hepatology.

[173]  T. Santantonio,et al.  Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. , 1999, Gastroenterology.

[174]  C. Trépo,et al.  Expression of Noncovalent Hepatitis C Virus Envelope E1-E2 Complexes Is Not Required for the Induction of Antibodies with Neutralizing Properties following DNA Immunization , 1999, Journal of Virology.

[175]  J. Silver,et al.  Replication of Subgenomic Hepatitis C Virus Rnas in a Hepatoma Cell Line , 1999 .

[176]  S. Emerson,et al.  DNA immunization of mice and macaques with plasmids encoding hepatitis C virus envelope E2 protein expressed intracellularly and on the cell surface. , 1999, Vaccine.

[177]  P Parham,et al.  Analysis of a successful immune response against hepatitis C virus. , 1999, Immunity.

[178]  C. Rice,et al.  Long-Term Follow-Up of Chimpanzees Inoculated with the First Infectious Clone for Hepatitis C Virus , 1999, Journal of Virology.

[179]  Y. Sung,et al.  Enhanced cellular immunity to hepatitis C virus nonstructural proteins by codelivery of granulocyte macrophage-colony stimulating factor gene in intramuscular DNA immunization. , 1999, Vaccine.

[180]  R. Thomssen,et al.  Low density lipoprotein receptor as a candidate receptor for hepatitis C virus , 1999, Journal of medical virology.

[181]  A Sette,et al.  Identification of HLA-A3 and -B7-restricted CTL response to hepatitis C virus in patients with acute and chronic hepatitis C. , 1999, Journal of immunology.

[182]  H. T. Head,et al.  Global surveillance and control of hepatitis C , 1999 .

[183]  C. Mandl,et al.  In vitro-synthesized infectious RNA as an attenuated live vaccine in a flavivirus model , 1998, Nature Medicine.

[184]  J. Encke,et al.  Genetic immunization generates cellular and humoral immune responses against the nonstructural proteins of the hepatitis C virus in a murine model. , 1998, Journal of immunology.

[185]  M. Houghton,et al.  Binding of hepatitis C virus to CD81. , 1998, Science.

[186]  Alan S. Perelson,et al.  Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy , 1998 .

[187]  M. Houghton,et al.  High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C , 1998, Hepatology.

[188]  Yoshiharu Matsuura,et al.  The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice , 1998, Nature Medicine.

[189]  F Tsuda,et al.  The entire nucleotide sequences of three hepatitis C virus isolates in genetic groups 7-9 and comparison with those in the other eight genetic groups. , 1998, The Journal of general virology.

[190]  Watanabe,et al.  Porphyria cutanea tarda and hepatitis C virus infection , 1998, The British journal of dermatology.

[191]  F. Ebeling.  Epidemiology of the Hepatitis C Virus , 1998, Vox sanguinis.

[192]  D. Samuel,et al.  Incidence of Hepatitis C in Patients Receiving Different Preparations of Hepatitis B Immunoglobulins after Liver Transplantation , 1998, Annals of Internal Medicine.

[193]  C. Trépo,et al.  In vivo tropism of hepatitis C virus genomic sequences in hematopoietic cells: influence of viral load, viral genotype, and cell phenotype. , 1998, Blood.

[194]  D. Wong,et al.  Hepatitis C Virus Structural Proteins Assemble into Viruslike Particles in Insect Cells , 1998, Journal of Virology.

[195]  E. Tanzi,et al.  Multicenter trial on mother‐to‐infant transmission of GBV‐C virus , 1998, Journal of medical virology.

[196]  B. Altun,et al.  Rapidly progressive glomerulonephritis associated with hepatitis C virus infection. , 1998, Clinical nephrology.

[197]  R. Chapman,et al.  Clinical outcome of hypogammaglobulinaemic patients following outbreak of acute hepatitis C: 2 year follow up , 1997, Clinical and experimental immunology.

[198]  J. Dubuisson,et al.  Immunization with plasmid DNA encoding hepatitis C virus envelope E2 antigenic domains induces antibodies whose immune reactivity is linked to the injection mode , 1997, Journal of virology.

[199]  M. Stazi,et al.  Sexual transmission of the hepatitis C virus and efficacy of prophylaxis with intramuscular immune serum globulin. A randomized controlled trial. , 1997, Archives of internal medicine.

[200]  K Koike,et al.  Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. , 1997, The Journal of general virology.

[201]  C. Trépo,et al.  DNA vaccination for the induction of immune responses against hepatitis C virus proteins. , 1997, Vaccine.

[202]  M. Picardi,et al.  High prevalence of hepatitis C virus infection in patients with B‐cell lymphoproliferative disorders in Italy , 1997, American journal of hematology.

[203]  J. Berzofsky,et al.  Plasmid DNA-based immunization for hepatitis C virus structural proteins: immune responses in mice. , 1997, Gastroenterology.

[204]  M. Battegay,et al.  A specific antibody response to HCV E2 elicited in mice by intramuscular inoculation of plasmid DNA containing coding sequences for E2 , 1997, Hepatology.

[205]  Y. Liaw,et al.  Detection of type 2‐like T‐helper cells in hepatitis C virus infection: Implications for hepatitis C virus chronicity , 1997, Hepatology.

[206]  J. Prieto,et al.  Induction of cytotoxic T‐cell response against hepatitis C virus structural antigens using a defective recombinant adenovirus , 1997, Hepatology.

[207]  J. Wands,et al.  Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids. , 1997, Journal of immunology.

[208]  M. Shapiro,et al.  Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[209]  C. Bréchot.  Hepatitis C virus , 1996, Digestive Diseases and Sciences.

[210]  M. Lenzi,et al.  Quantification of hepatitis C virus-infected peripheral blood mononuclear cells by in situ reverse transcriptase-polymerase chain reaction. , 1996, Blood.

[211]  M. Massari,et al.  Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. , 1996, The Journal of clinical investigation.

[212]  V. Zurawski,et al.  Expression and immune response to hepatitis C virus core DNA–based vaccine constructs , 1996, Hepatology.

[213]  K. Meyer,et al.  Hepatitis C virus core protein cooperates with ras and transforms primary rat embryo fibroblasts to tumorigenic phenotype , 1996, Journal of virology.

[214]  C Crimi,et al.  Identification of A2-restricted hepatitis C virus-specific cytotoxic T lymphocyte epitopes from conserved regions of the viral genome. , 1996, International immunology.

[215]  M. Alter,et al.  Effect of immune globulin on the prevention of experimental hepatitis C virus infection. , 1996, The Journal of infectious diseases.

[216]  M. Houghton,et al.  A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[217]  T. Santantonio,et al.  Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection , 1995, The Lancet.

[218]  K. Meyer,et al.  Immune responses to plasmid DNA encoding the hepatitis C virus core protein , 1995, Journal of virology.

[219]  R. Purcell,et al.  Genetic Heterogeneity of Hepatitis C Virus: Quasispecies and Genotypes , 1995, Seminars in liver disease.

[220]  S. Frøland,et al.  Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. , 1994, The New England journal of medicine.

[221]  M. Shapiro,et al.  Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[222]  N. Kato,et al.  Genetic drift in hypervariable region 1 of the viral genome in persistent hepatitis C virus infection , 1994, Journal of virology.

[223]  J. Berzofsky,et al.  An epitope in hepatitis C virus core region recognized by cytotoxic T cells in mice and humans , 1994, Journal of virology.

[224]  A. Weiner,et al.  Vaccination of chimpanzees against infection by the hepatitis C virus. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[225]  D. Weiner,et al.  Genetic infection induces protective in vivo immune responses. , 1993, DNA and cell biology.

[226]  N. Kato,et al.  Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus , 1993, Journal of virology.

[227]  K. Ching,et al.  A unique, predominant hepatitis C virus variant found in an infant born to a mother with multiple variants , 1993, Journal of virology.

[228]  J. Ulmer,et al.  Heterologous protection against influenza by injection of DNA encoding a viral protein. , 1993, Science.

[229]  N. Ogata,et al.  Lack of protective immunity against reinfection with hepatitis C virus , 1992 .

[230]  Giorgio,et al.  Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[231]  D. Tang,et al.  Genetic immunization is a simple method for eliciting an immune response , 1992, Nature.

[232]  G. Pasero,et al.  Association between hepatitis C virus and mixed cryoglobulinemia [see comment]. , 1991, Clinical and experimental rheumatology.

[233]  Matthew J. Brauer,et al.  Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. , 1991, Virology.

[234]  G. Acsadi,et al.  Direct gene transfer into mouse muscle in vivo. , 1990, Science.

[235]  M. Houghton,et al.  Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. , 1989, Science.

[236]  J. Desmyter,et al.  LYME BORRELIOSIS IN BELGIUM , 1987, The Lancet.

[237]  R. Knodell,et al.  EFFICACY OF PROPHYLACTIC GAMMA-GLOBULIN IN PREVENTING NON-A, NON-B POST-TRANSFUSION HEPATITIS , 1976, The Lancet.

[238]  T. Baumert,et al.  Hepatitis C virus entry. , 2013, Current topics in microbiology and immunology.

[239]  R. Thimme,et al.  Adaptive immune responses in hepatitis C virus infection. , 2013, Current topics in microbiology and immunology.

[240]  M. Kohara,et al.  An experimental mouse model for hepatitis C virus. , 2011, Experimental animals.

[241]  S. Ray,et al.  Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. , 2010, Gastroenterology.

[242]  D. Burton,et al.  Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge , 2008, Nature Medicine.

[243]  H J Alter,et al.  Recovery, Persistence, and Sequelae in Hepatitis C Virus Infection: A Perspective on Long-Term Outcome , 2000, Seminars in liver disease.

[244]  J. Hernández,et al.  Detection of HCV and GBV-CHGV RNA in peripheral blood mononuclear cells of patients with chronic type C hepatitis. , 2000, Microbios.

[245]  R. Bhat,et al.  Immune responses to hepatitis C virus structural and nonstructural proteins induced by plasmid DNA immunizations. , 2000, The Journal of infectious diseases.

[246]  T. Liang,et al.  Development of a plant-derived subunit vaccine candidate against hepatitis C virus , 2000, Archives of Virology.

[247]  T. Shikata,et al.  Experimental vaccine activities of recombinant E1 and E2 glycoproteins and hypervariable region 1 peptides of hepatitis C virus in chimpanzees , 1999, Archives of Virology.

[248]  T. Gojobori,et al.  Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization , 1998, Archives of Virology.

[249]  B. Moss,et al.  Prospects for prophylactic and therapeutic hepatitis C virus vaccines. , 1995, Princess Takamatsu symposia.

[250]  G. Pasero,et al.  Association between hepatitis C virus and mixed cryoglobulinemia , 1991 .